There have been several promising advancements in the treatment of lung cancer, with new drugs and clinical trials showing significant potential.

1. Repotrectinib for ROS1-Positive NSCLC: Repotrectinib has shown impressive results in shrinking tumors in patients with ROS1-positive non-small cell lung cancer (NSCLC). In the TRIDENT-1 trial, nearly 80% of patients who had not previously received a ROS1-targeted drug responded to the treatment, with a median progression-free survival of nearly 36 months. This drug also demonstrated effectiveness against brain metastases​ (Comprehensive Cancer Information)​​ (Memorial Sloan Kettering Cancer Center)​.
2. Biomarker-Directed Combinations: Research from MD Anderson Cancer Center has highlighted the effectiveness of combining targeted therapy with immunotherapy for patients with immunotherapy-resistant NSCLC. This approach helps overcome immune resistance and reinvigorate anti-tumor activity, offering new hope for patients who do not respond to standard treatments​ (MD Anderson Cancer Center)​.
3. Tarlatamab for Small Cell Lung Cancer (SCLC): Tarlatamab, a new drug for previously treated extensive-stage SCLC, has shown promising results. In the DeLLphi-301 trial, the median overall survival was 14.3 months, significantly longer than the typical 6-12 months with current treatments. This drug targets DLL3 on tumor cells and activates T cells to kill cancer cells​ (Comprehensive Cancer Information)​.
4. Clinical Trials in 2023 and Beyond: Several clinical trials are currently recruiting participants, including studies on:
   • Single-fraction Stereotactic Body Radiation Therapy (SBRT): This pilot study aims to evaluate the effectiveness of a one-dose SBRT approach for NSCLC, potentially reducing treatment costs and increasing convenience​ (Lung Cancer Center)​.
   • Neoantigen Vaccine for SCLC: A Phase II study at Washington University School of Medicine is investigating a personalized neoantigen vaccine combined with durvalumab to improve progression-free survival in patients with extensive-stage SCLC​ (Lung Cancer Center)​.

These new treatments and clinical trials represent significant steps forward in the fight against lung cancer, offering patients more options and improved outcomes. For more information about participating in clinical trials, you can visit the websites of institutions like the National Cancer Institute, MD Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center.